Tertiary pain-clinic records show mixed erythromelalgia treatment responses

Erythromelalgia in a tertiary pain clinic: a comprehensive database study of clinical features and treatment experience.

Acta neurologica Belgica β€’ β€’ Moderately Relevant
πŸ€–

AI Summary

This observational database study examined clinical features and documented treatment experiences among 23 people with erythromelalgia identified in a tertiary pain clinic’s records. Symptoms and diagnostic certainty varied: burning pain was documented in 16/23, while erythema or warmth was documented in 17/23. The study’s main treatment finding was that commonly used oral therapies more often had records of no benefit or intolerance than benefit. For cannabis, benefit was documented in 6/9 cases, but the reported benefit was often nonspecific.

Intravenous lidocaine-magnesium was documented as beneficial in 5/8 cases, usually with transient effects; no recorded feature clearly separated patients with and without benefit. Because this was a small review of clinical records, and treatment responses were not assessed in a controlled comparison, the findings cannot establish which treatments work best or prove that cannabis was responsible for reported benefit. This is an abstract-based summary; the study does not establish comparative efficacy.

πŸ’‘ Key Findings

1
In this observational review, commonly used oral therapies more often had documented non-benefit or intolerance than benefit.
High
90%
2
For cannabis, 6/9 cases had documented benefit, often described as nonspecific; the records cannot establish that cannabis caused the improvement.
High
90%
3
Intravenous lidocaine-magnesium benefit was documented in 5/8 cases and was usually transient.
High
90%
4
The 23 cases showed varied clinical features and diagnostic certainty, and no recorded feature clearly distinguished patients with and without treatment benefit.
High
90%

πŸ“„ Original Abstract

BACKGROUND: Erythromelalgia is a rare, clinically heterogeneous disorder characterized by distal burning pain, erythema, and warmth. Evidence from routine tertiary pain practice is limited. METHODS: We searched our institution's pain-clinic records dated 23 June 2009-1 June 2026 for erythromelalgia-related terms and characterized phenotype, etiologic evaluation, treatment exposure, and response. RESULTS: Among 58,650 patients represented by 1,260,439 document rows, we identified 23 cases: 16 female; median age at first relevant record, 35 years; 4 definite, 7 probable, and 12 possible. Burning pain was documented in 16/23, erythema or warmth in 17/23, characteristic provocation in 10/23, and cooling or trigger-removal relief in 6/23. Benefit versus non-benefit or intolerance was 5/16 versus 8/16 for gabapentinoids, 3/11 versus 5/11 for antidepressants, 1/9 versus 7/9 for oral sodium-channel blockers, and 0/8 versus 5/8 for opioids. Intravenous lidocaine-magnesium benefit was documented in 5/8, usually transient; cannabis benefit in 6/9 was often nonspecific. CONCLUSION: This study characterizes the clinical heterogeneity and treatment experience of erythromelalgia in tertiary pain practice. Commonly used oral therapies more often had documented non-benefit or intolerance, including after possible cases were excluded, and no recorded feature clearly distinguished patients with and without benefit. These observations do not establish comparative efficacy. The findings support careful phenotype assessment, structured, time-limited treatment trials with predefined pain and functional goals, and prospective evaluation of the magnitude and durability of the intravenous lidocaine-magnesium signal.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.